103 related articles for article (PubMed ID: 8318321)
21. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
[TBL] [Abstract][Full Text] [Related]
22. The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and their glucuronide conjugates in surgical patients.
Koopman-Kimenai PM; Vree TB; Booij LH; Dirksen R
Int J Clin Pharmacol Ther; 1995 Aug; 33(8):442-8. PubMed ID: 8556223
[TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M
Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069
[TBL] [Abstract][Full Text] [Related]
24. The disposition and cerebrospinal fluid penetration of morphine and its two major glucuronidated metabolites in adults undergoing lumbar myelogram.
Laizure SC; Miller JH; Stevens RC; Donahue DJ; Laster RE; Brown D
Pharmacotherapy; 1993; 13(5):471-5. PubMed ID: 8247914
[TBL] [Abstract][Full Text] [Related]
25. Kinetics of morphine in patients with renal failure.
Säwe J; Odar-Cederlöf I
Eur J Clin Pharmacol; 1987; 32(4):377-82. PubMed ID: 3609116
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer.
Mashayekhi SO; Ghandforoush-Sattari M; Routledge PA; Hain RD
Biopharm Drug Dispos; 2009 Apr; 30(3):99-106. PubMed ID: 19260034
[TBL] [Abstract][Full Text] [Related]
27. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.
Bouw MR; Xie R; Tunblad K; Hammarlund-Udenaes M
Br J Pharmacol; 2001 Dec; 134(8):1796-804. PubMed ID: 11739257
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure.
Aitkenhead AR; Vater M; Achola K; Cooper CM; Smith G
Br J Anaesth; 1984 Aug; 56(8):813-9. PubMed ID: 6743445
[TBL] [Abstract][Full Text] [Related]
29. Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep.
Milne RW; Sloan PA; McLean CF; Mather LE; Nation RL; Runciman WB; Rutten AJ; Somogyi AA
Drug Metab Dispos; 1993; 21(6):1151-6. PubMed ID: 7905398
[TBL] [Abstract][Full Text] [Related]
30. Morphine-6-glucuronide: an analgesic of the future?
Lötsch J; Geisslinger G
Clin Pharmacokinet; 2001; 40(7):485-99. PubMed ID: 11510626
[TBL] [Abstract][Full Text] [Related]
31. Ofloxacin pharmacokinetics in chronic renal failure and dialysis.
Lameire N; Rosenkranz B; Malerczyk V; Lehr KH; Veys N; Ringoir S
Clin Pharmacokinet; 1991 Nov; 21(5):357-71. PubMed ID: 1773550
[TBL] [Abstract][Full Text] [Related]
32. Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study.
Illum L; Davis SS; Pawula M; Fisher AN; Barrett DA; Farraj NF; Shaw PN
Biopharm Drug Dispos; 1996 Nov; 17(8):717-24. PubMed ID: 8950049
[TBL] [Abstract][Full Text] [Related]
33. Different distribution of morphine and morphine-6 beta-glucuronide after intracerebroventricular injection in rats.
Okura T; Saito M; Nakanishi M; Komiyama N; Fujii A; Yamada S; Kimura R
Br J Pharmacol; 2003 Sep; 140(1):211-7. PubMed ID: 12967951
[TBL] [Abstract][Full Text] [Related]
34. Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat.
Stain-Texier F; Sandouk P; Scherrmann JM
Drug Metab Dispos; 1998 May; 26(5):383-7. PubMed ID: 9571218
[TBL] [Abstract][Full Text] [Related]
35. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
36. Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide.
de Hoogd S; Välitalo PAJ; Dahan A; van Kralingen S; Coughtrie MMW; van Dongen EPA; van Ramshorst B; Knibbe CAJ
Clin Pharmacokinet; 2017 Dec; 56(12):1577-1587. PubMed ID: 28510797
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease.
Guay DR; Awni WM; Findlay JW; Halstenson CE; Abraham PA; Opsahl JA; Jones EC; Matzke GR
Clin Pharmacol Ther; 1988 Jan; 43(1):63-71. PubMed ID: 3335120
[TBL] [Abstract][Full Text] [Related]
38. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat.
Stain F; Barjavel MJ; Sandouk P; Plotkine M; Scherrmann JM; Bhargava HN
J Pharmacol Exp Ther; 1995 Aug; 274(2):852-7. PubMed ID: 7636748
[TBL] [Abstract][Full Text] [Related]
39. Ketoconazole kinetics in chronic peritoneal dialysis.
Johnson RJ; Blair AD; Ahmad S
Clin Pharmacol Ther; 1985 Mar; 37(3):325-9. PubMed ID: 3971656
[TBL] [Abstract][Full Text] [Related]
40. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites.
Hand CW; Sear JW; Uppington J; Ball MJ; McQuay HJ; Moore RA
Br J Anaesth; 1990 Mar; 64(3):276-82. PubMed ID: 2328175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
